Last Updated : September 14, 2023
Details
FilesProject Status:
Open for Stakeholder Feedback
Project Line:
Reimbursement Review
Project Sub Line:
Streamlined Drug Class Review
Project Number:
TS0002-000
The class of sodium-glucose cotransporter-2 (SGLT2) inhibitors is an integral part of the management of type 2 diabetes mellitus. Evidence informing the place in therapy of SGLT2 inhibitors has matured since CADTH last assessed this drug class. Public drug programs have requested a review to assess the optimal use of SGLT2 inhibitors after a trial of metformin.
This is a new CADTH project. Projects listed as “in progress” are at various stages and points of completion. These products have different processes and timelines; therefore, the timing of posting of the final reports varies. The Projects in Progress page on the CADTH website is updated on a seven to eight-day cycle. View other current Projects in Progress.
Call for feedback
Call for feedback:
Feedback Due By
Feedback Due By:
Consultation document
Consultation document:
Proposed Project Scope
Product Line
Product Line:
Reimbursement Review
Project Number
Project Number:
TS0002-000
| Posting of Draft Scope for stakeholder feedback | September 14 |
|---|---|
| End of feedback period | September 28 |
Files
Last Updated : September 14, 2023